Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 2, 2008, Pages 212-215

  Colombatto, P ^a   Ciccorossi, P ^a   Maina, A M ^a,b,c   Civitano, L ^a,b,c   Oliveri, F ^a   Coco, B ^a   Romagnoli, V ^a   Bonino, F ^b,c   Brunetto, M R ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; REBETRON; RIBAVIRIN; VIRUS RNA;

ADULT; ALGORITHM; ARTICLE; CELL COUNT; CHRONIC HEPATITIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IEOT MODEL; INFECTED CELL; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RAPID VIROLOGICAL RESPONSE; RELAPSE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; VIRUS GENE; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG CARRIERS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-2; KINETICS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, THEORETICAL; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; ROC CURVE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 49149090985     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.21     Document Type: Article

References (20)

1. Manns, M.P. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001).
2. Fried, M.W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
3. Hadziyannis, S.J. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346-355 (2004).
4. Strader, D.B., Wright, T., Thomas, D.L. & Seeff, L.B.; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 39, 1147-1171 (2004).
5. Mangia, A. et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 352, 2609-2617 (2005).
6. von Wagner, M. et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129, 522-527 (2005).
7. Zeuzem, S. et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. 44, 97-103 (2006).
8. Jensen, D.M. et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43, 954-960 (2006).
9. Yu, M. et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 56, 553-559 (2007).
10. Shiffman, M.L. et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 357, 124-134 (2007).
11. Willems, B. et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virological response? J. Hepatol. 46, S6 (2007).
12. Sanchez-Tapias, J.M. et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131, 451-460 (2006).
13. Berg, T. et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130, 1086-1097 (2006).
14. Marcellin, P. et al. Host and viral baseline characteristics in hepatitis C naive and non-responder patients: comparison of three large randomized multinational trials. J. Hepatol. 46, S232 (2007).
15. Westin, J. et al. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J. Viral Hepat. 14, 29-35 (2007).
16. Medeiros-Filho, J.E. et al. Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy. World J. Gastroenterol. 12, 7271-7277 (2006).
17. Neumann, A.U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282, 103-107 (1998).
18. Ribeiro, R.M, Layden-Almer, J., Powers, K.A., Layden, T.J. & Perelson, A.S. Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 38, 509-517 (2003).
19. Colombatto, P. et al. Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir. Ther. 8, 519-530 (2003).
20. Ferenci, P. et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J. Hepatol. 43, 425-433 (2005).